Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical SOR007 for Cervical Intraepithelial Neoplasia
NCT03143491Phase 2Withdrawn
- Sponsor
- DFB Soria
- Start
- Oct 2017
- Primary completion
- Dec 2018
01
Overview
Phase 2, open-label trial of SOR007 Ointment Placebo in cervical intraepithelial neoplasia (CIN) (3 arms), sponsored by DFB Soria. Primary endpoint: Incidence of treatment emergent adverse events at 49 days. Planned start Oct 2017; status: withdrawn.
02
Drugs
SOR007 Ointment Placebo
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT03143491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03143491.